Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the
Zacks Style Scores, helps address this issue for us.
Below, we take a look at
Immunocore Holdings PLC Sponsored ADR (, a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score. IMCR Quick Quote IMCR - Free Report)
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Immunocore Holdings PLC Sponsored ADR currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of
Zacks #1 Rank Stocks here >>> Set to Beat the Market?
In order to see if IMCR is a promising momentum pick, let's examine some Momentum Style elements to see if this company holds up.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For IMCR, shares are up 2.88% over the past week while the Zacks Medical - Biomedical and Genetics industry is down 2.42% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 15.97% compares favorably with the industry's 0.69% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Immunocore Holdings PLC Sponsored ADR have increased 63.64% over the past quarter, and have gained 69.82% in the last year. On the other hand, the S&P 500 has only moved 0.37% and -7.81%, respectively.
Investors should also pay attention to IMCR's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. IMCR is currently averaging 218,913 shares for the last 20 days.
The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with IMCR.
Over the past two months, 4 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost IMCR's consensus estimate, increasing from -$2.64 to -$1.34 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.
Given these factors, it shouldn't be surprising that IMCR is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Immunocore Holdings PLC Sponsored ADR on your short list.